Cellipont Bioservices, a leading cell therapy CDMO, and CellVax Therapeutics, a clinical-stage biotech company, have expanded their partnership to support the manufacturing of FK-GI101, a personalized immunotherapy for gastric, pancreatic, and colon cancers. The collaboration builds on their earlier work with FK-PC101, currently in Phase II trials for high-risk prostate cancer.

The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product, and facility readiness for FK-GI101 and FK-PC101.

FK-GI101 uses a patient’s own tumor cells collected during surgery. These are modified to express MHC Class II molecules to boost immune recognition, then irradiated to prevent replication before being returned to the patient to trigger a targeted immune response.

"Expanding our partnership with Cellipont is a critical step in scaling our personalized immunotherapy platform," said Fernando Kreutz, CEO, CellVax Therapeutics.

"We’re proud to deepen our collaboration as CellVax brings this platform to GI cancers, where new treatments are urgently needed," said Darren Head, CEO, Cellipont Bioservices.